RNA polymerase II subunit K pseudogene 2Genealiases: []
Q-omics provides the consensus-scored POLR2KP2 profile across patient tissues and cancer cell-line models. POLR2KP2 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in GBM. Among the 18 cancer types available for tumor–normal comparison, POLR2KP2 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, POLR2KP2 RNA expression shows 7,499 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight GBM, STAD, and BRCA as cancer lineages where POLR2KP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2KP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2KP2 survival associations across molecular data types. POLR2KP2 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2KP2 RNA expression–survival associations across cancer types. High POLR2KP2 expression shows unfavorable associations in GBM, ESCA, LGG, LUSC and PAAD, but favorable associations in LUAD. The GBM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify GBM as the clearest survival context for POLR2KP2 RNA expression.
This table summarizes POLR2KP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for POLR2KP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2KP2 shows lower tumor expression in LUSC and higher tumor expression in STAD. The STAD box plot shows higher POLR2KP2 RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p = .040).
This table shows molecular features associated with POLR2KP2 in patient tissues and cancer cell lines. In patient samples, POLR2KP2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
